SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Tokai Pharmaceuticals Initiates ARMOR Clinical Development Program for TOK-001; First Ever Multi-Target Investigational Drug for Prostate Cancer